Epizyme Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced the pricing of its public offering of 13,333,334 shares of its common stock at a price of $9.00 per share before underwriting discounts. All of the shares of common stock to be sold in the offering are to be sold by Epizyme. In addition, Epizyme has granted to the underwriters a 30-day option to purchase up to 2,000,000 additional shares of common stock at the public offering price, less the underwriting discount.

Epizyme intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to:

• Fund the global development costs of tazemetostat, Epizyme’s novel oral EZH2 inhibitor, outside of Japan, including the costs of the following clinical trials:
  • the ongoing five-arm phase 2 study in patients with non-Hodgkin lymphoma;
  • the recently initiated phase 2 study in adult patients with INI1-negative tumors, certain SMARCA4-negative tumors or synovial sarcoma;
  • the recently initiated phase 1 study in pediatric patients with INI1-negative tumors, certain SMARCA4-negative tumors or synovial sarcoma;
  • the planned clinical trial of tazemetostat in combination with R-CHOP in front-line elderly patients with diffuse large B-cell lymphoma;
  • the planned clinical trial of tazemetostat in combination with a B-cell signaling agent or immuno-oncology agent in patients with B-cell non-Hodgkin lymphoma; and
  • the planned phase 2 study of tazemetostat in BAP1-mutated mesothelioma;
• Initiate market development activities, begin building regulatory and commercial strategies to prepare for the global launch of tazemetostat, if approved, and expand the company’s clinical and regulatory capabilities;
• Fund research and development to advance the company’s pipeline of preclinical product candidates and its programs that are subject to the Celgene collaboration and to expand its drug development platform; and
• For working capital and other general corporate purposes.

Citigroup, Leerink Partners LLC and RBC Capital Markets, LLC are acting as joint book-running managers for the offering. JMP Securities and Wedbush PacGrow are acting as co-lead managers for the offering, with Mizuho Securities, H.C. Wainwright & Co., LLC and Maxim Group LLC acting as co-managers. The offering is expected to close on or about January 12, 2016, subject to customary closing conditions.

A shelf registration statement relating to the shares of common stock offered in the public offering was filed with the Securities and Exchange Commission (SEC) on May 4, 2015, and declared effective by the SEC on May 29, 2015. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement related to the offering has been filed with the SEC and may be obtained for free by visiting EDGAR on the SEC website at www.sec.gov. A final prospectus supplement related to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained by contacting Citigroup Global Markets Inc., c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] or by phone at 800-831-9146; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at [email protected], or by phone at 1-800-808-7525 ext. 6142; or RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY 10281-8098; Attention: Equity Syndicate; Phone: 877-822-4089; Email: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary drug discovery platform that the company uses to create small molecule inhibitors of chromatin modifying proteins (CMPs) such as histone methyltransferases (HMTs). Using its proprietary platform, the company has built a pipeline of programs led by its novel inhibitor of the EZH2 HMT, tazemetostat. Based on data from an ongoing phase 1 clinical trial, tazemetostat is being evaluated in multiple registration-supporting trials for the potential treatment of non-Hodgkin lymphoma and certain genetically defined solid tumors. The company is currently conducting a phase 2 study of tazemetostat in patients with relapsed/refractory non-Hodgkin lymphoma, a phase 2 study in adult patients with INI1-negative solid tumors, certain SMARCA4-negative solid tumors or synovial sarcoma, and a phase 1 study in pediatric patients with INI1-negative solid tumors, certain SMARCA4-negative solid tumors or synovial sarcoma.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Epizyme, Inc., including statements about the Company’s public offering, anticipated use of proceeds, future operations, clinical development of the Company's therapeutic candidates, expectations regarding future clinical trials and future expectations and plans and prospects for the Company and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, uncertainties inherent in the initiation of future clinical trials and such other factors as are set forth in the risk factors detailed in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2015 and the preliminary prospectus supplement filed with the SEC on January 5, 2016 under the heading “Risk Factors,” and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160106006802/en/

Epizyme, Inc.
Andrew Singer, 617-500-0712
Executive Vice President and Chief Financial Officer
[email protected]
or
THRUST Investor Relations
Monique Allaire, 617-895-9511
[email protected]

Source: Epizyme, Inc.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• YY Group Holding (YYGH) Closes $5M IPO
• Nanometrics (NANO) Issues Business Update, Reports FY23 Results